13F Pro13F Pro

Soleus Capital Management, L.P.

Institutional InvestorSimilar funds →SEC EDGAR: CIK 1802630
Institutional-grade research for retail investors

Sector Allocation

  • Healthcare99.7%$2.9B
  • Technology0.3%$9.2M

AUM History

13fpro.ai/research/fund/soleus-capital-management-l-p-1802630

Conviction and streaks

Diversifying · top 10 = 48.9%

From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.

KRYS$KRYSConviction hold12.0% weight · held 10 quartersCELC$CELCConviction hold6.1% weight · held 10 quartersTGTX$TGTXConviction hold5.5% weight · held 10 quartersNVCR$NVCRConviction hold5.2% weight · held 7 quartersUTHR$UTHRConviction hold4.2% weight · held 10 quartersGERN$GERNAccumulating+1684% shares · 5 quarters runningANIP$ANIPAccumulating+1610% shares · 4 quarters runningKIDS$KIDSAccumulating+1527% shares · 4 quarters runningPODD$PODDAccumulating+6163% shares · 3 quarters runningUTHR$UTHRAccumulating+276% shares · 2 quarters runningPRAX$PRAXTrimming-84% shares · 5 quarters runningTWST$TWSTTrimming-94% shares · 3 quarters runningAXGN$AXGNTrimming-97% shares · 3 quarters runningCGON$CGONTrimming-98% shares · 3 quarters runningGMED$GMEDTrimming-47% shares · 2 quarters running

Largest positions — Q2 2026

Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.

13fpro.ai/research/fund/soleus-capital-management-l-p-1802630

Soleus Capital Management, L.P. 13F holdings — Q2 2026

$2.9B portfolio (+17.5% QoQ) · 97 holdings · Q2 2026 13F · top 10 are 49% of the stock portfolio

All holdings — Soleus Capital Management, L.P. (Q2 2026)

97 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.

Company
VCEL$VCELVericel Corp$64.9M-43%
PRAX$PRAXPraxis Precision Medicines, Inc.$59.4M-46%
GERN$GERNGERON CORP$54.8M+3%
ALKS$ALKSAlkermes plc.$53.9M-48%
ERAS$ERASErasca, Inc.$49.5MNew
NPCE$NPCENeuroPace Inc$46.3M-0.7%
PGNY$PGNYProgyny, Inc.$46.2M-22%
INDV$INDVIndivior Pharmaceuticals, Inc.$43.7M-16%
PBLS$PBLSParabilis Medicines, Inc.$40.1MNew
FOCL$FOCLEDAP TMS SAadr$37.9M—
GMED$GMEDGLOBUS MEDICAL INC$37.0M-36%
RCUS$RCUSArcus Biosciences, Inc.$36.0M+159%
SNDX$SNDXSyndax Pharmaceuticals Inc$35.6M-6%
NRIX$NRIXNurix Therapeutics, Inc.$35.5M+56%
LEGN$LEGNLegend Biotech Corpadr$34.8MNew

What changed in Q2 2026

Against the previous quarter's 13F: 21 new, 25 added to, 42 trimmed, 17 sold out. Share-count changes; largest moves by dollar size first.

New positions (21)

  • ERAS$ERASErasca, Inc.$49.5M

    first bought this quarter

  • PBLS$PBLSParabilis Medicines, Inc.$40.1M

    first bought this quarter

  • LEGN$LEGNLegend Biotech Corp$34.8M

    first bought this quarter

  • UNH$UNHUNITEDHEALTH GROUP INC$33.3M

    first bought this quarter

  • PALI$PALIPALISADE BIO, INC.$27.3M

    first bought this quarter

  • SUPN$SUPNSUPERNUS PHARMACEUTICALS, INC.$24.2M

    first bought this quarter

+15 more in the Excel export

Added to (25)

  • PODD$PODDINSULET CORP+86%

    now $159.7M · held 3 qtrs, 3 adds in a row

  • INSP$INSPInspire Medical Systems, Inc.+235%

    now $86.2M · held 6 qtrs, 2 adds in a row

  • CELC$CELCCelcuity Inc.+33%

    now $178.3M · held 10+ qtrs

  • AVTX$AVTXAvalo Therapeutics, Inc.+274%

    now $30.6M · held 3 qtrs

  • RCUS$RCUSArcus Biosciences, Inc.+159%

    now $36.0M · held 3 qtrs

  • UTHR$UTHRUNITED THERAPEUTICS Corp+21%

    now $122.2M · held 10+ qtrs, 2 adds in a row

+19 more in the Excel export

Trimmed (42)

  • TWST$TWSTTwist Bioscience Corp-91%

    now $10.8M · held 5 qtrs, 2 trims in a row

  • KRYS$KRYSKrystal Biotech, Inc.-19%

    now $349.1M · held 10+ qtrs

  • IMUX$IMUXIMMUNIC, INC.-90%

    now $6.9M · held 2 qtrs

  • TGTX$TGTXTG THERAPEUTICS, INC.-27%

    now $160.9M · held 10+ qtrs

  • PRAX$PRAXPraxis Precision Medicines, Inc.-46%

    now $59.4M · held 10+ qtrs, 5 trims in a row

  • ALKS$ALKSAlkermes plc.-48%

    now $53.9M · held 3 qtrs

+36 more in the Excel export

Sold out (17)

  • PCVX$PCVXVaxcyte, Inc.was $22.4M

    held 2 qtrs

  • ICLR$ICLRICON PLCwas $21.2M

    held 1 qtr

  • TVTX$TVTXTravere Therapeutics, Inc.was $16.2M

    held 1 qtr

  • INBX$INBXInhibrx Biosciences, Inc.was $8.8M

    held 2 qtrs

  • DXCM$DXCMDEXCOM INCwas $8.8M

    held 2 qtrs

  • ETON$ETONEton Pharmaceuticals, Inc.was $4.1M

+11 more in the Excel export

Firm AUM (Form ADV): $3.7B as of 2025-12-31 · SEC IAPD

Share

Holdings by quarter

Every 13F Soleus Capital Management, L.P. has filed, 26 earlier quarters. Pick one to see what it held then.

Email me the moment this fund files its next 13FPro

Is it too late to follow Soleus Capital Management, L.P.?

Q2 2026 13F filed with the SEC on Aug 11, 2026. Prices are closing prices as of Oct 26, 2026.

Average quality of Soleus Capital Management, L.P.'s top 20 holdings: 66/100 (our AI quality score, weighted by position size; 13 of the 20 are scored)

Top 10 since filing

-0.5%

Value-weighted move of the 10 largest stock positions

Turnover

29%

Last quarter; 129% over the last 4

Top 10 weight

49%

Share of the stock portfolio in its 10 largest positions

Held 4+ quarters

70%

Share of portfolio value in positions held a year or more

Highest-quality names it owns(among its 100 largest positions)

The 8 highest-scoring companies in this portfolio are a Pro feature.

How these are measured
  • Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
  • Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
  • Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q1 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
  • Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
  • Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.

Portfolio Overview

Soleus Capital Management, L.P. disclosed 97 positions worth $2.9B in its Form 13F-HR for Q2 2026, led by $KRYS (Krystal Biotech, Inc.) at 12.0% of the equity portfolio, followed by $CELC and $TGTX. During the quarter the fund opened 21 new positions and exited 17 — including a new stake in $ERAS and a full exit from $PCVX. The portfolio is most concentrated in Healthcare (99.7% of disclosed assets). All figures are sourced directly from Soleus Capital Management, L.P.’s Form 13F-HR filing with the SEC under CIK 1802630.

Funds like this

managers whose biggest positions overlap Soleus Capital Management, L.P.'s
Avoro Capital Advisors LLC$11.14B 13F book · 4 shared top holdingsKRYSUTHRCELCAVTXDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)$9.59B 13F book · 10 shared top holdingsCELCUTHRPRAXLEGNBAKER BROS. ADVISORS LP$19.96B 13F book · 4 shared top holdingsCELCPRAXALKSNRIXRedmile Group, LLC$1.49B 13F book · 4 shared top holdingsKRYSNRIXBMRNLIVNVestal Point Capital, LP$4.28B 13F book · 7 shared top holdingsUTHRPODDGMEDNRIXPERCEPTIVE ADVISORS LLC$6.66B 13F book · 4 shared top holdingsCELCPRAXNRIXTNGX

Browse Top Institutional Investors

13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.

Berkshire HathawayBridgewater AssociatesCitadel AdvisorsRenaissance TechnologiesTwo Sigma InvestmentsDE Shaw & CoMillennium ManagementAQR Capital ManagementPoint72 Asset ManagementTiger Global ManagementVanguard GroupBlackRock

to search all 8,700+ institutional filers.

AI-Powered Hedge Fund Analysis: Soleus Capital Management, L.P.

13F Pro is an AI hedge fund tracker and stock research platform. For Soleus Capital Management, L.P. (SEC CIK: 1802630), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.

Every holding in Soleus Capital Management, L.P.'s portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.